Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug Conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The companys' flagship product Adcetris is commercially available for two indications in 50 countries, including the U.S., Canada, Japan and members of the European Union. The approval of Brentuximab vedotin makes it the first in a new class of ADCs.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the terms of the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.
|Key people||Clay B. Siegall Ph.D (Chairman, President & CEO) Todd E. Simpson (CFO Eric L. Dobmeier (Chief Operating Officer) Jean Liu (Executive Vice President Legal Affairs, General Counsel, Corporate Secretary) Jonathan Drachman M.D. (Chief Medical Officer) and Executive Vice President of R&D) Vaughn Himes (Executive Vice President) Technical Operations and Process Sciences Charles Romp (Senior Vice President) Sales Felix Baker Lead Independent Director Pinkston Peggy Senior Director Corporate Communications|
|Products||Brentuximab vedotin and other Antibody-drug conjugates|
|Headquarters||Bothell, Washington, United States|
|Founded||Incorporated 15 July 1997|
Net Promoter Score is a number from -100 from 100.
The industry average for Health Care / Biotechnology: Biological Products (No Diagnostic Substances) is 0.
Consider an example: If Seattle Genetics, Inc. sends out NPS surveys immediately after purchase, they are tracking their customers' initial excitement and the checkout experience.
Therefore, comparing the NPS score of Seattle Genetics, Inc. with your own without any further context is not that useful.
|Telfort||Telecommunications / Wireless Carrier||-3|
|Comcast||Consumer Brands / Car Manufacturers||-3|
|CIGNA||Insurance / Health and Life Insurance||-1|
|Chase||Financial Services / Banking||-1|
|Vodafone||Telecommunications / Wireless Carrier||-1|
|Ocado||Consumer Brands / Grocery||-4|
|Time Warner||Telecommunications / Cable/TV service||-5|
|Time Warner Cable||Telecommunications / Cable/TV service||-5|
|Sky||Telecommunications / Cable/TV service||-5|
|BBC||Media / Cable/TV service||-5|
We have estimated the Net Promoter Score of Seattle Genetics, Inc. based on the publicly available information
including the sentiment of the company-related tweets, 3rd party reviews, and Alexa ratings.